KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Current Leases (2019 - 2025)

Pacific Biosciences Of California has reported Current Leases over the past 7 years, most recently at $448000.0 for Q4 2025.

  • Quarterly results put Current Leases at $448000.0 for Q4 2025, down 95.53% from a year ago — trailing twelve months through Dec 2025 was $448000.0 (down 95.53% YoY), and the annual figure for FY2025 was $448000.0, down 95.53%.
  • Current Leases for Q4 2025 was $448000.0 at Pacific Biosciences Of California, down from $621000.0 in the prior quarter.
  • Over the last five years, Current Leases for PACB hit a ceiling of $12.5 million in Q2 2024 and a floor of $448000.0 in Q4 2025.
  • Median Current Leases over the past 5 years was $8.6 million (2022), compared with a mean of $7.1 million.
  • Biggest five-year swings in Current Leases: soared 81.12% in 2022 and later tumbled 95.53% in 2025.
  • Pacific Biosciences Of California's Current Leases stood at $7.7 million in 2021, then increased by 15.25% to $8.9 million in 2022, then rose by 7.93% to $9.6 million in 2023, then rose by 4.54% to $10.0 million in 2024, then tumbled by 95.53% to $448000.0 in 2025.
  • The last three reported values for Current Leases were $448000.0 (Q4 2025), $621000.0 (Q3 2025), and $703000.0 (Q2 2025) per Business Quant data.